Thus, it is anticipated that GCGR activation may become a trail blazer in the field of thermogenic therapeutics, not only enhancing the weight loss profile of current therapies, but also that of other anti-obesity medications that function by reducing daily caloric intake. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.